Business Context and Reporting Period
Company: Microbot Medical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 10, 2026
Reporting Period: Event-based (April 10, 2026)
Business Context: The Company is reporting on the status of its "At the Market" (ATM) equity offering program. Microbot Medical Inc. is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol "MBOT."
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The only financial metric disclosed relates to the equity offering program:
- ATM Program Aggregate Offering Price: Up to $39,230,691.
Material Changes
The filing does not report material changes to financial results or operations compared to a prior period. The primary disclosure is the administrative update regarding the Company's existing ATM Program, originally established on June 10, 2021, and amended on July 1, 2024. The Company intends to file a prospectus supplement with the SEC to facilitate the offer and sale of shares under this program.
Guidance, Outlook, and Risks
Management Commentary: The Company may sell common stock from time to time through H.C. Wainwright & Co., LLC. Sales will be made via transactions deemed "at the market offerings" under Rule 415, including sales on the Nasdaq Capital Market or to market makers at prevailing market prices.
Risks and Contingencies: The filing explicitly states that it does not constitute an offer to sell or a solicitation of an offer to buy shares in any jurisdiction where such an offer would be unlawful prior to registration. Sales are contingent upon the filing of a prospectus supplement.
Investor Verification Checklist
- Verify the filing of the Prospectus Supplement on Form S-3 (File No. 333-275634) referenced in the report.
- Confirm the current remaining capacity of the $39,230,691 ATM Program by reviewing recent 10-Q or 10-K filings.
- Review the legal opinion filed as Exhibit 5.1 regarding the validity of the ATM Shares.
- Monitor subsequent 8-K filings for actual sales executed under the ATM Program.